Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic equivalence of new salmeterol HFA inhaler vs existing salmeterol CFC inhaler in asthma
2005-004744-32Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of salmeterol in asthma (2 arms), sponsored by Merck & Co. Primary endpoints: Change in FEV1 at 1 hour after administration, Change in FEV1 at 2 hours 10 minutes after administration and 1 more. Started Oct 2005; status: completed.
02
Drugs
salmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2005-004744-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004744-32.